NICM
RVNC

Neo Ivy Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Neo Ivy Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,952
Closed -$606K – 480
2023
Q2 		$606K Buy
+23,952
New +$746K 0.32% 113

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Neo Ivy Capital Management's RVNC Position: Q3 2023 in Review

Neo Ivy Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 23,952 shares — an estimated $606K sold.

Neo Ivy Capital Management first reported a position in RVNC in Q2 2023 and held it in 1 quarter. The position peaked at $606K in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Neo Ivy Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Neo Ivy Capital Management sold 23,952 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $606K.
  • Neo Ivy Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 1 quarter.
  • Neo Ivy Capital Management's Revance Therapeutics, Inc. position peaked at $606K in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Neo Ivy Capital Management's 13F filing for Q3 2023, filed 30 Nov 2023.